CFM
ACAD icon

Crawford Fund Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Crawford Fund Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-19,800
Closed -$363K – 188
2024
Q4 		$363K Buy
+19,800
New +$320K 0.06% 185

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

Crawford Fund Management's ACAD Position: Q1 2025 in Review

Crawford Fund Management sold out of Acadia Pharmaceuticals (ACAD) in Q1 2025, closing a stake of 19,800 shares — an estimated $363K sold.

Crawford Fund Management first reported a position in ACAD in Q4 2024 and held it in 1 quarter. The position peaked at $363K in Q4 2024. 320 funds tracked by Wall St. Rank hold ACAD as of Q1 2025.

  • Crawford Fund Management reported no remaining Acadia Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Crawford Fund Management sold 19,800 Acadia Pharmaceuticals shares in Q1 2025, an estimated $363K.
  • Crawford Fund Management first reported a position in Acadia Pharmaceuticals in Q4 2024 and held it in 1 quarter.
  • Crawford Fund Management's Acadia Pharmaceuticals position peaked at $363K in Q4 2024.
  • 320 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2025.

Based on Crawford Fund Management's 13F filing for Q1 2025, filed 15 May 2025.